These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35889320)

  • 21. Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
    Cox S; Margot N; Ram R; Johnson A; Miller M; Callebaut C
    Antiviral Res; 2017 Jul; 143():22-29. PubMed ID: 28363735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers.
    Ji X; Li Y; Wang Z; Gao Y; Wang L
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):168-179. PubMed ID: 37953690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
    Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Kashuba ADM; Wira CR
    Sci Rep; 2017 Dec; 7(1):17697. PubMed ID: 29255206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
    Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
    Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
    Birkus G; Bam RA; Willkom M; Frey CR; Tsai L; Stray KM; Yant SR; Cihlar T
    Antimicrob Agents Chemother; 2016 Jan; 60(1):316-22. PubMed ID: 26503655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
    J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method.
    Yang N; Zhou G; Cheng X; He J; Chen Y; Chen C; Li M; Ge J; Wang M; Zhang T; Ge W; Zhu H; Han G
    Front Pharmacol; 2021; 12():734760. PubMed ID: 34483946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
    Ma Q; Ocque AJ; Morse GD; Sanders C; Burgi A; Little SJ; Letendre SL
    Clin Infect Dis; 2020 Aug; 71(4):982-988. PubMed ID: 31560741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
    Heron JE; Bloch M; Vanguru V; Saunders J; Gracey DM
    BMC Nephrol; 2020 Aug; 21(1):339. PubMed ID: 32787843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
    Custodio JM; Fordyce M; Garner W; Vimal M; Ling KH; Kearney BP; Ramanathan S
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5135-40. PubMed ID: 27216057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Parsons TL; Gwenden KN; Marzinke MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32540983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.